| Schedule of Segment Reporting Information, by Segment |
The following tables summarize, for the periods indicated, operating results by reportable segment: Cost of goods sold is directly related to product sales only. Revenues derived from co-promote revenue had no cost of goods sold. | | | | | | Pharmaceutical | | | | | | | | | | | | | | and | | | | | | | | | | | Dermatology | | Biotechnology | | | | | | | | | ($ in thousands) | | Products | | Product | | | | | | | | | Three Months Ended June 30, 2018 | | Sales | | Development | | National | | Consolidated | | | Net Revenue | | $ | 6,689 | | | 126 | | $ | 57,019 | | $ | 63,834 | | | Direct cost of goods | | | (1,668) | | | | | | | | | (1,668) | | | Sales and marketing costs | | | (2,910) | | | | | | | | | (2,910) | | | Research and development | | | | | | (17,489) | | | | | | (17,489) | | | General and administrative | | | (383) | | | (9,763) | | | | | | (10,146) | | | National expenses | | | | | | | | | (56,218) | | | (56,218) | | | Segment income (loss) from operations | | | 1,728 | | | (27,126) | | | 801 | | | (24,597) | | | Segment assets | | $ | 11,307 | | $ | 159,763 | | | 65,796 | | $ | 236,866 | |
| | | | | | Pharmaceutical | | | | | | | | | | | | | | And | | | | | | | | | | | Dermatology | | Biotechnology | | | | | | | | | ($ in thousands) | | Products | | Product | | | | | | | | | Three Months Ended June 30, 2017 | | Sales | | Development | | National | | Consolidated | | | Net Revenue | | $ | 4,054 | | $ | 350 | | $ | 46,293 | | $ | 50,697 | | | Direct cost of goods | | | (878) | | | | | | | | | (878) | | | Sales and marketing costs | | | (2,610) | | | | | | | | | (2,610) | | | Research and development | | | | | | (13,483) | | | | | | (13,483) | | | General and administrative | | | (293) | | | (8,231) | | | | | | (8,524) | | | National expenses | | | | | | | | | (48,395) | | | (48,395) | | | Segment loss from operations | | | 273 | | | (21,364) | | | (2,102) | | | (23,193) | | | Segment assets | | $ | 5,447 | | $ | 167,787 | | $ | 76,612 | | $ | 249,846 | |
| | | | | | Pharmaceutical | | | | | | | | | | | | | | And | | | | | | | | | | | Dermatology | | Biotechnology | | | | | | | | | ($ in thousands) | | Products | | Product | | | | | | | | | Six Months Ended June 30, 2018 | | Sales | | Development | | National | | Consolidated | | | Net Revenue | | $ | 12,198 | | $ | 520 | | $ | 106,541 | | $ | 119,259 | | | Direct cost of goods | | | (3,140) | | | | | | | | | (3,140) | | | Sales and marketing costs | | | (5,670) | | | | | | | | | (5,670) | | | Research and development | | | | | | (42,544) | | | | | | (42,544) | | | General and administrative | | | (783) | | | (20,151) | | | | | | (20,934) | | | National expenses | | | | | | | | | (107,054) | | | (107,054) | | | Segment loss from operations | | $ | 2,605 | | | (62,175) | | $ | (513) | | $ | (60,083) | | | Segment assets | | $ | 11,307 | | | 159,763 | | $ | 65,796 | | $ | 236,866 | |
| | | | | | Pharmaceutical | | | | | | | | | | | | | | And | | | | | | | | | | | Dermatology | | Biotechnology | | | | | | | | | ($ in thousands) | | Products | | Product | | | | | | | | | Six Months Ended June 30, 2017 | | Sales | | Development | | National | | Consolidated | | | Net Revenue | | $ | 6,139 | | $ | 1,043 | | $ | 88,197 | | $ | 95,379 | | | Direct cost of goods | | | (1,347) | | | - | | | - | | | (1,347) | | | Sales and marketing costs | | | (4,877) | | | - | | | - | | | (4,877) | | | Research and development | | | | | | (21,887) | | | - | | | (21,887) | | | General and administrative | | | (612) | | | (15,897) | | | - | | | (16,509) | | | National expenses | | | - | | | - | | | (91,529) | | | (91,529) | | | Segment income (loss) from operations | | $ | (697) | | $ | (36,741) | | $ | (3,332) | | $ | (40,770) | | | Segment assets | | $ | 5,447 | | $ | 167,787 | | $ | 76,612 | | $ | 249,846 |
|
|